

EGFR

Human anti-EGFR (Necitumumab) mAb

Catalog No.	CSB109A CSB109B	Quantity:	200 µg 1.0 mg
Alternate Names:	11F8, IMC-11F8, LY3012211, Portrazza		
Description:	Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).		
Concentration:	1.0 mg/ml		
UniProt ID (target):	P00533		
Source:	CHO cell line		
Isotype:	Human IgG1 kappa		
INN:	Necitumumab		
Specificity:	Human epidermal growth factor receptor		
Biologic Activity:	EGFR antagonist		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.